Robert Joseph March Sells 4,775 Shares of BioSyent Inc. (CVE:RX) Stock

BioSyent Inc. (CVE:RX) Senior Officer Robert Joseph March sold 4,775 shares of the company’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of C$11.65, for a total value of C$55,628.75.

BioSyent Price Performance

CVE RX traded down C$0.10 during mid-day trading on Thursday, hitting C$11.60. The stock had a trading volume of 5,689 shares, compared to its average volume of 6,600. The company has a 50 day simple moving average of C$11.18 and a 200 day simple moving average of C$10.51. The company has a quick ratio of 6.91, a current ratio of 6.13 and a debt-to-equity ratio of 3.19. The company has a market cap of C$134.44 million, a price-to-earnings ratio of 19.50 and a beta of 0.93. BioSyent Inc. has a 52-week low of C$8.24 and a 52-week high of C$11.74.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.